药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Pembrolizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pembrolizumab.
Mecasermin
Nivolumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Nivolumab.
Mecasermin
Raxibacumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Raxibacumab.
Mecasermin
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Brentuximab vedotin.
Mecasermin
Volociximab
The risk or severity of adverse effects can be increased when Volociximab is combined with Brentuximab vedotin.
Mecasermin
Catumaxomab
The risk or severity of adverse effects can be increased when Catumaxomab is combined with Brentuximab vedotin.
Mecasermin
Teplizumab
The risk or severity of adverse effects can be increased when Teplizumab is combined with Brentuximab vedotin.
Mecasermin
Reslizumab
The risk or severity of adverse effects can be increased when Reslizumab is combined with Brentuximab vedotin.
Mecasermin
Lexatumumab
The risk or severity of adverse effects can be increased when Lexatumumab is combined with Brentuximab vedotin.
Mecasermin
Lerdelimumab
The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Brentuximab vedotin.
Mecasermin
Bivatuzumab
The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Brentuximab vedotin.
Mecasermin
Sibrotuzumab
The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Brentuximab vedotin.
Mecasermin
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Brentuximab vedotin.
Mecasermin
Siplizumab
The risk or severity of adverse effects can be increased when Siplizumab is combined with Brentuximab vedotin.
Mecasermin
Pertuzumab
The risk or severity of adverse effects can be increased when Pertuzumab is combined with Brentuximab vedotin.
Mecasermin
Lucatumumab
The risk or severity of adverse effects can be increased when Lucatumumab is combined with Brentuximab vedotin.
Mecasermin
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brentuximab vedotin.
Mecasermin
XmAb 2513
The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Brentuximab vedotin.
Mecasermin
Carotuximab
The risk or severity of adverse effects can be increased when Carotuximab is combined with Brentuximab vedotin.
Mecasermin
Elotuzumab
The risk or severity of adverse effects can be increased when Elotuzumab is combined with Brentuximab vedotin.